Selepressin in Septic Shock
Authors:
- 1 June 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Shock
- Vol. 57 (6) , 172-179
Abstract
Sepsis and septic shock usually show a high mortality rate and frequently need of intensive care unit admissions. After fluid resuscitation, norepinephrine (NE) is the first-choice vasopressor in septic shock patients. However, high-NE doses are associated with increased rates of adverse effects and mortality. In this perspective, many authors have proposed the administration of non-adrenergic vasopressors (NAV). Selepressin is a selective vasopressin type 1A (V1A) receptor agonist and may be a valid option in this field, because it can decrease NE requirements and also limit the deleterious effects induced by high doses of catecholamines. Only few clinical data actually support selepressin administration in this setting. Here, we review the current literature on this topic analyzing some pathophysiological aspects, the rationale about the use of NAV, the possible use of selepressin differentiating animal, and human studies. Various issues remain unresolved and future trials should be focused on early interventions based on a multimodal activation of the vasopressive pathways using both alpha and V1A receptors pathways.Keywords
This publication has 34 references indexed in Scilit:
- Myocardial depression in sepsis: From pathogenesis to clinical manifestations and treatmentJournal of Critical Care, 2014
- High versus Low Blood-Pressure Target in Patients with Septic ShockNew England Journal of Medicine, 2014
- Selepressin, a New V1A Receptor AgonistShock, 2013
- Role of selective V1a receptor agonism in ovine septic shock*Critical Care Medicine, 2011
- Multicenter Study of Central Venous Oxygen Saturation (ScvO2) as a Predictor of Mortality in Patients With SepsisAnnals of Emergency Medicine, 2010
- Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trialCritical Care, 2009
- Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot studyCritical Care, 2009
- A comparison of epinephrine and norepinephrine in critically ill patientsIntensive Care Medicine, 2008
- Vasopressin versus Norepinephrine Infusion in Patients with Septic ShockNew England Journal of Medicine, 2008
- Decreased vasopressin responsiveness in vasodilatory septic shock–like conditions*Critical Care Medicine, 2006